https://www.vumedi.com/video/year-in-review-2024-key-clinical-trials-in-prostate-cancer/, 视频播放量 6、弹幕量 0、点赞数 0、投硬币枚数 0、收藏人数 0、转发人数 0, 视频作者 enjoy_cc, 作者简介 ,相关视频:
The ZERO Prostate Cancer Support Community connects patients, families, friends and caregivers to enhance the quality of life for all those affected by prostate cancer. This community is sponsored by ZERO Prostate Cancer, an Inspire trusted partner.
A Correction to this article was published on 14 March 2022This article has been updatedAbstract Objective Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm, phase II ...
Schellhammer, P., Clinical trials in prostate cancer. BJU Int, 2003. 92(3): p. 186-7.P., Schellhammer. (2003) Clinical trials in prostate cancer. BJU International 92 , 186-187 /P. Schellhammer. (2003) Clinical trials in prostate cancer. BJU International 92 , 186-187 /...
“ADT reminds me of a dripping faucet, because there are still some hormones like testosterone being made by the tumour. We have clinical evidence that treating prostate cancer with ADT alone is no longer enough,” Yu explains. “With today’s ARIs, there’s so little testosterone in the ...
PROSTATE CANCER - LIMITED UPDATE MARCH 2022 11 1. INTRODUCTION 1.1 Aims and scope The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa. It must be emphasised that clinical guidelines present the best...
Trials volume 23, Article number: 12 (2022) Cite this article 2898 Accesses 3 Citations 2 Altmetric Metrics details Abstract Background Men with localized prostate cancer often experience urinary, sexual, bowel, and hormonal symptoms; general distress; pain; fatigue; and sleep disturbance. For me...
By 2022, the newly reported cases and deaths due to PC in China increased to 134,200 and 47,500, respectively. Thus, early diagnosis and standardized treatment for prostate cancer in China remain far-reaching objectives. Burgeoning research on advanced PC and castration-resistant prostate cancer ...
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic
Prostate cancer is the second most common malignancy among males [1,2]. It is estimated that over 1.2 million new cases of prostate cancer and over 350,000 related death will occur each year [1,2]. Over the past decade, significant progresses have been achieved in the clinical treatments ...